Treatment | PRNT50a | Survival rate (%) |
|---|
Prime | 1stboost | 2ndboost |
|---|
rMVA-mep | 105TCID50 | <5 | <8 | 20±1.33 | 60c |
106 TCID50 | <7 | 9±1.33 | 33±2.33* | 85c |
107 TCID50 | <8 | 18±2.33* | 56±1.01** | 100c |
Inactivated JEV vaccine | 9±1.33* | 29±1.02** | 58±2.01** | 100c |
EDIII | 8±2.00* | 28±1.99** | 56±1.99** | 100c |
rMEP | 9±1.01* | 27±2.01** | 57±1.99** | 100c |
Wild MVAb | -- | -- | -- | 0 |
PBSb | -- | -- | -- | 8.33 |
- a Prime-boost-boost vaccinations (days 0, 14 and 28) with rMVA-mep were carried out. On day 14 (prime), day 28 (first boost) and day 42 (second boost) sera were taken and analyzed. 50% plaque reduction neutralizing titer (PRNT50) was shown as the geometrical reciprocal of the sera dilution resulting in a 50% reduction.
- b No JEV-neutralizing antibodies were detectable in 1:2 diluted sera of the mice in the PBS and wild MVA groups. n = 12, values represent the mean ± standard error. Standard group is rMVA/M (105 TCID50).
- * Significance [p< 0.05 to animals immunized with rMVA/M (105TCID50)].
- **Significance [p<0.01 to animals immunized with rMVA/M (105TCID50)].
- c Significance (p< 0.05 to 8.33%).
